摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Methyl-1-cyclopentenylmethylether | 42285-04-1

中文名称
——
中文别名
——
英文名称
Methyl-1-cyclopentenylmethylether
英文别名
1-(Methoxymethyl)cyclopentene
Methyl-1-cyclopentenylmethylether化学式
CAS
42285-04-1
化学式
C7H12O
mdl
——
分子量
112.172
InChiKey
GZJKQTJFKHOCNN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    8
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • Inhibitors of c-Jun N-terminal kinases
    申请人:Liu Gang
    公开号:US20060173050A1
    公开(公告)日:2006-08-03
    The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.
    本发明涉及作为c-jun N-末端激酶1、2或3(JNK1、JNK2或JNK3)抑制剂的化合物,包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
  • Pyrimidine derivatives as ghrelin receptor modulators
    申请人:Kosogof Christi
    公开号:US20050070712A1
    公开(公告)日:2005-03-31
    The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.
    本发明涉及式(I)的化合物,或者其治疗上适宜的盐或前药,该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物,包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
  • Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
    申请人:Kosogof Christi
    公开号:US20050171131A1
    公开(公告)日:2005-08-04
    The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.
    本发明涉及式(I)的化合物,或其治疗上适用的盐或前药,所述化合物的制备,含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物,包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖,以及与肥胖相关的疾病,如非胰岛素依赖型糖尿病。
  • Piperazine Compounds with Herbicidal Effect
    申请人:Parra Rapado Liliana
    公开号:US20110130286A1
    公开(公告)日:2011-06-02
    Piperazine compounds of the formula I in which the variables are defined according to the description, their agriculturally suitable salts, processes and intermediates for preparing the piperazine compounds of the formula I, compositions comprising them and their use as herbicides, i.e. for controlling harmful plants, and also a method for controlling unwanted vegetation which comprises allowing a herbicidally effective amount of at least one piperazine compound of the formula I to act on plants, their seed and/or their habitat.
    化学式I中变量根据描述定义的哌嗪化合物,其在农业上适用的盐,制备化学式I中哌嗪化合物的过程和中间体,包含它们的组合物以及它们作为除草剂的用途,即用于控制有害植物,还包括一种控制不良植被的方法,其中包括让至少一种化学式I中的哌嗪化合物对植物、它们的种子和/或它们的栖息地产生除草作用的有效量。
  • Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
    申请人:Xin Zhili
    公开号:US20050171132A1
    公开(公告)日:2005-08-04
    The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity and disorders associated with obesity such as non-insulin dependent diabetes mellitus.
    本发明涉及式(I)的化合物,或其治疗上适宜的盐或前药,以及该化合物的制备、含有该化合物的组合物以及在预防或治疗由胃饥饿素受体调节的疾病中使用该化合物,包括普拉德-威利综合症、进食障碍、体重增加、饮食和运动后体重减轻维持、肥胖症以及与肥胖症相关的疾病,如非胰岛素依赖性糖尿病。
查看更多